Table 2.

The association of EBF with HIV infection, within strata of potential modifiers during the 12-month follow-up

Potential modifier	HIV +ve	N	RR (95% CI)a	P a	Pintb
Maternal ARV therapy
No	53	1287	0.86 (0.73–1.00)	0.05	0.37
Yes	18	308	0.74 (0.51–1.08)	0.11
Maternal baseline CD4+ cell count (/mm3)
<350	29	379	0.83 (0.63–1.10)	0.2	0.2
≥350	35	1088	0.83 (0.69–0.99)	0.04
Maternal baseline CD8+ cell count (/mm3)
<767	4	357	–c		0.62
≥767	57	1079	0.82 (0.71–0.94)	0.006
Maternal baseline lymphocyte count (/mm3)
<2000	7	324	0.84 (0.35–2.02)	0.75	0.69
≥2000	54	1116	0.85 (0.73–0.99)	0.04

^aRR, 95% CI and p-values are from the adjusted Cox-PH regression models. Covariates adjusted for were the same as in Table 1.

^b p-value, tests for interaction between EBF and potential modifiers were obtained from likelihood ratio tests.

^cRR could not be estimated in the multivariate model because of the small number of events.